- Home
- ZNTL vs PSBD Comparison
ZNTL vs PSBD Comparison
Compare ZNTL & PSBD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ZNTL | PSBD |
|---|---|---|
| Founded | 2014 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 313.9M | 333.6M |
| IPO Year | 2020 | 2019 |
Fundamental Metrics
Financial Performance| Metric | ZNTL | PSBD |
|---|---|---|
| Price | $4.06 | $10.87 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 5 | 9 |
| Target Price | $6.60 | ★ $12.33 |
| AVG Volume (30 Days) | ★ 1.0M | 101.3K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 15.02% |
| EPS Growth | ★ 18.03 | N/A |
| EPS | N/A | ★ 1.66 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $6.54 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.13 | $9.34 |
| 52 Week High | $6.95 | $14.96 |
Technical Indicators
Market Signals| Indicator | ZNTL | PSBD |
|---|---|---|
| Relative Strength Index (RSI) | 51.88 | 53.15 |
| Support Level | $3.75 | $10.28 |
| Resistance Level | $4.40 | $11.14 |
| Average True Range (ATR) | 0.32 | 0.39 |
| MACD | -0.05 | -0.02 |
| Stochastic Oscillator | 59.20 | 50.51 |
Price Performance
Historical ComparisonAbout ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
About PSBD Palmer Square Capital BDC Inc.
Palmer Square Capital BDC Inc is a financial services company that lends to and invests in corporate debt securities of companies, including small to large private U.S. companies. Their investment objective is to maximize total return, comprised of current income and capital appreciation.